Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2025)

Catalyst Pharmaceuticals' EBT Margin history spans 11 years, with the latest figure at 47.11% for Q4 2025.

  • For Q4 2025, EBT Margin fell 519.0% year-over-year to 47.11%; the TTM value through Dec 2025 reached 48.14%, up 416.0%, while the annual FY2025 figure was 48.14%, 416.0% up from the prior year.
  • EBT Margin reached 47.11% in Q4 2025 per CPRX's latest filing, down from 47.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 54.33% in Q4 2022 to a low of 37.03% in Q3 2023.
  • Average EBT Margin over 5 years is 40.23%, with a median of 44.94% recorded in 2022.
  • Peak YoY movement for EBT Margin: crashed -8246bps in 2023, then skyrocketed 8148bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 33.45% in 2021, then skyrocketed by 62bps to 54.33% in 2022, then fell by -22bps to 42.24% in 2023, then increased by 24bps to 52.31% in 2024, then dropped by -10bps to 47.11% in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EBT Margin are 47.11% (Q4 2025), 47.87% (Q3 2025), and 47.28% (Q2 2025).